Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Adaptimmune Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
Tickers ADAP
From GlobeNewswire News Releases
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
Tickers ADAP
From GlobeNewswire News Releases
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Q3 Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
Tickers ADAP
From GlobeNewswire News Releases
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Q2 Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Q1 Financial Results
Tickers ADAP
From GlobeNewswire News Releases
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
Tickers ADAP
From GlobeNewswire News Releases
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Tickers ADAP
From GlobeNewswire News Releases
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Tickers ADAP
From GlobeNewswire News Releases
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options 
Tickers ADAP
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.